Catalog No.
Product Name
Application
Product Information
Citations
-
ROS/NLRP3 Inflammasome Activator
Trimethylamine N-oxide dihydrate is an activator of the ROS/NLRP3 inflammasome, functioning as a gut microbe-derived metabolite of dietary choline and other trimethylamine-rich nutrients. This compound promotes inflammatory responses and plays a role in the differentiation of fibroblasts to myofibroblasts, thereby contributing to cardiac fibrosis through the activation of the TGF-β/smad2 signaling pathway. Its properties make it valuable in studies focused on inflammation and fibrosis mechanisms in various biological contexts. -
Stable Isotope
Trimethylamine N-oxide-d9 is a deuterium-labeled form of Trimethylamine N-oxide, a gut microbiome-dependent metabolite derived from dietary choline and trimethylamine-rich nutrients. This compound has been shown to induce inflammation through the activation of the ROS/NLRP3 inflammasome. Additionally, Trimethylamine N-oxide is involved in accelerating fibroblast-to-myofibroblast differentiation, promoting cardiac fibrosis via the TGF-β/smad2 signaling pathway. It is a valuable reagent for research on metabolic disorders and cardiovascular diseases. -
NLRX1 Activator
Amelenodor is an NLRX1 activator that induces immunometabolic changes by selectively targeting the NLRX1 pathway. This compound demonstrates potential in reducing inflammation and modulating immune responses in inflammatory bowel diseases. Research applications include studies on Crohn's disease and ulcerative colitis, making it a valuable tool for advancing understanding of these conditions. -
NLRP3 Inhibitor
Selnoflast (RO7486967) is a highly selective and reversible small molecule inhibitor of the NLRP3 inflammasome. It effectively inhibits the release of IL-1β in response to NLRP3 activation in human monocyte-derived macrophages associated with Alzheimer's disease. Selnoflast is a valuable reagent for research into Alzheimer's disease and systemic inflammatory conditions, including ulcerative colitis and chronic obstructive pulmonary disease. -
AQP9 Inhibitor
RG100204 is a selective inhibitor of the aquaporin 9 (AQP9), targeting its channel function to obstruct the transmembrane transport of water, glycerol, and hydrogen peroxide (H2O2). This compound exhibits significant anti-inflammatory activity by reducing the activation of the NLRP3 inflammasome and the p38 MAPK signaling pathways, leading to decreased inflammation and pyroptosis. In preclinical studies, RG100204 has demonstrated the ability to mitigate multi-organ dysfunction in mouse models of sepsis and has shown potential glucose-regulating effects in diabetic db/db mice. -
NLRP3 Inhibitor
Ruvonoflast is a selective and orally active inhibitor of the NLRP3 inflammasome, effectively penetrating the central nervous system. With an IC50 of 0.32 nM, it inhibits IL-1β release in human peripheral blood mononuclear cells. Upon intracellular conversion to its active carboxylic acid form, Ruvonoflast demonstrates the ability to reverse obesity, systemic inflammation, and astrogliosis in mouse models of diet-induced obesity. This compound holds promise for research into neurodegenerative diseases such as Alzheimer's, Parkinson's, multiple sclerosis, and amyotrophic lateral sclerosis. -
NLRP3 Inflammasome Inhibitor
NP3-253 is a potent NLRP3 inflammasome inhibitor that exhibits oral bioavailability and can penetrate the blood-brain barrier. By acting as a molecular glue, NP3-253 stabilizes the NLRP3 protein in an inactive state, thereby effectively reducing the production of pro-inflammatory cytokines, including IL-1β and IL-18. This compound is valuable for studying inflammatory processes and neurological disorders, such as peritonitis, providing insights into therapeutic strategies for these conditions. -
NLRP3 Inhibitor
AZD4144 is a selective NLRP3 inhibitor with an effective concentration (EC50) of 0.082 μM. This compound significantly reduces the release of IL-1β associated with NLRP3 overactivation, demonstrating pronounced anti-inflammatory properties. With minimal impact on hERG and low cardiotoxicity, AZD4144 serves as a valuable tool for investigating diseases linked to NLRP3 inflammasome activation. -
NLRP3 Inflammasome Inhibitor
(±)11(12)-EET functions as an inhibitor of the NLRP3 inflammasome, playing a significant role in modulating inflammatory processes. This compound demonstrates potential anti-inflammatory, angiogenic, and cardioprotective properties, making it valuable for research aimed at understanding and treating inflammatory diseases and cardiovascular conditions. Its use in preclinical studies can provide insights into the mechanisms underlying these biological activities. -
KCNK13 Inhibitor
CVN293 is a selective inhibitor of the potassium ion channel KCNK13, demonstrating IC50 values of 41 nM and 28 nM for human and mouse KCNK13, respectively. This compound effectively suppresses the NLRP3 inflammasome-mediated production of the proinflammatory cytokine IL-1β in microglial cells. CVN293's brain permeability and targeted action make it a valuable tool for researching neuroinflammatory processes and potential therapeutic interventions. -
Inflammatory Corpuscles Inhibitor
JC2-11 is an inhibitor of inflammatory corpuscles that targets domain-containing proteins NLRC4 and AIM2, as well as non-canonical inflammatory pathways. This compound is effective in reducing the secretion of caspase-1 (p20) and the cleavage of gasdermin D (GSDMD), leading to decreased release of IL-1β and lactate dehydrogenases (LDH) from inflammatory bodies. JC2-11 also disrupts the activation of inflammatory corpuscles by inhibiting reactive oxygen species production and caspase-1 activity, making it a valuable tool for research into inflammation and related diseases. -
NLRP3/AIM2 Inhibitor
NLRP3/AIM2-IN-2 is a selective inhibitor targeting the NLRP3 and AIM2 inflammasomes, demonstrating potent species-specific effects on inflammasome-dependent cell death. With an IC50 value of 0.2392 µM, this compound serves as a valuable tool for investigating the role of NLRP3 and AIM2 in inflammatory processes and cell death pathways. Its use can provide insights into therapeutic strategies for diseases characterized by dysregulated inflammasome activity. -
NLRP3 Inhibitor
BAL-0028 is a reversible inhibitor of the NLRP3 inflammasome, demonstrating an IC50 of 25 nM. This compound selectively binds to the NACHT domain of NLRP3, with KD values ranging from 104 to 123 nM. BAL-0028 effectively inhibits the secretion of IL-1β, exhibiting notable anti-inflammatory properties, making it a valuable tool in research focused on inflammatory diseases and immune responses. -
Anti-inflammatory Agent
Maresin 2 is a pro-resolving mediator derived from human macrophages, primarily acting as an anti-inflammatory agent. This compound belongs to the maresin family of lipid mediators, biosynthesized from docosahexaenoic acid (DHA). Maresin 2 plays a crucial role in tissue inflammation resolution and has potential applications in research focused on inflammatory diseases and regenerative medicine. -
P2 Receptor Inhibitor
Oxidized ATP trisodium salt is an irreversible antagonist of P2 receptors, particularly effective against P2X7R activation. This compound has been shown to inhibit c-reactive protein (CRP)-induced activation of the NLRP3 inflammasome, thereby modulating inflammatory responses. Oxidized ATP trisodium salt is a valuable tool for research applications related to atherosclerosis and other inflammatory conditions. -
NLRP3 Inflammasome Inhibitor
NDT-19795 is a potent inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 66 nM in peripheral blood mononuclear cells (PBMC) and 4.7 μM in Western blot assays. This carboxylic acid-active compound is an active metabolite of NT-0796, contributing to its efficacy within cellular contexts. NDT-19795 is applicable in research focused on inflammatory pathways and neurological disorders, providing valuable insights into the modulation of the NLRP3 inflammasome. -
Potassium Channel Inhibitor
DPO-1 is a selective inhibitor of Kv1.5 and Kv1.3 potassium channels (EC50 = 3.1 μM) with notable immunomodulatory and anti-inflammatory properties. It effectively reduces Kv1.3 current density, diminishes Ca2+ influx in calcium-depleted Jurkat cells, and inhibits IL-2 secretion in activated Jurkat cells. Additionally, DPO-1 obstructs uric acid sodium (MSU)-induced NLRP3 inflammasome activation by interfering with Kv1.5-mediated K+ efflux. This reagent is valuable for research into immunological disorders and atrial fibrillation. -
NLRP3 Inhibitor
JT002 is a selective inhibitor of the NLRP3 inflammasome assembly. It effectively reduces the production of NLRP3-dependent proinflammatory cytokines, including IL-1β, IL-1α, and IL-18, while also inhibiting pyroptosis. In preclinical studies, JT002 demonstrated the ability to mitigate airway hyperresponsiveness and airway neutrophilia in murine models, making it a valuable tool for investigating various inflammatory diseases, such as Muckle-Wells syndrome. -
NLRP3 Inhibitor
NLRP3-IN-13 is a selective and potent inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value of 2.1 μM. This compound effectively inhibits both NLRP3 and NLRC4 inflammasome activity, as well as NLRP3-mediated interleukin-1 beta (IL-1β) production. Additionally, NLRP3-IN-13 disrupts NLRP3 ATPase activity, making it a valuable tool for investigating neuroinflammatory disorders and related pathways. -
NLRP3 Inhibitor
JC124 is a selective inhibitor of the NLRP3 inflammasome, a crucial component in the inflammatory response. It demonstrates significant anti-inflammatory activities and provides neuroprotective effects, making it a valuable tool in research aimed at understanding neuroinflammation and related disorders. JC124 is suitable for studies investigating the modulation of inflammatory pathways and potential therapeutic interventions in various neurological conditions. -
NLRP3 Inhibitor
INF 195 is a potent NLRP3 inhibitor that effectively suppresses NLRP3-driven macrophage pyroptosis and interleukin-1 beta (IL-1β) release, exhibiting an EC50 value of 0.15 μM. This compound has demonstrated the ability to reduce infarct size in isolated mouse hearts at low doses, thereby providing protection against myocardial ischemia/reperfusion injury. INF 195 serves as a valuable tool for research focused on inflammation and cardiovascular diseases. -
NF-κB Inhibitor
Ergolide is a selective NF-κB/p65 and NLRP3 inhibitor that effectively disrupts the NF-κB signaling pathway and inhibits the nuclear translocation of p65. By irreversibly binding to the NACHT domain of NLRP3, Ergolie suppresses inflammasome assembly, significantly reducing the production of inflammatory mediators such as NO and PGE2. This compound promotes apoptosis in cancer cells, induces autophagy, and generates reactive oxygen species (ROS). Ergolide also enhances the therapeutic efficacy of vincristine and has been shown to alleviate acute lung injury in models of sepsis and inflammation, contributing to research in metastatic uveal melanoma, neurodegenerative diseases, and acute lymphoblastic leukemia. -
NLRP3 Inhibitor
Emlenoflast (MCC7840) is a potent and selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of less than 100 nM. This sulfonylurea compound plays a critical role in modulating inflammatory responses and is valuable for research into various inflammatory diseases. Its ability to inhibit the NLRP3 pathway makes it a significant tool for investigating mechanisms of inflammation and developing therapeutic strategies. -
NLRP3 Selective Agonist
2-Guanidinobezimidazole is a selective agonist of the NLRP3 inflammasome, exhibiting a KD value of 1.29 μM towards His-GFP-NLRP3. By binding directly to the leucine-rich repeat (LRR) domain of NLRP3, it facilitates inflammasome assembly and activation. This compound is pertinent for research into anti-tumor immunity, demonstrating potential to inhibit tumor growth and address resistance to immune checkpoint blockade (ICB). -
NLRP3 Antagonist
NLRP3 Antagonist 1 is a selective antagonist of the NLRP3 inflammasome, primarily expressed in macrophages and neutrophils. This compound plays a crucial role in modulating the innate immune response to pathogenic infections and cellular stress. NLRP3 Antagonist 1 has potential applications in cancer research and other inflammatory diseases, providing a valuable tool for studying the underlying mechanisms of NLRP3-mediated pathways. -
NLRP3 Inflammasome Inhibitor
YQ128 is a potent and selective second-generation inhibitor of the NLRP3 inflammasome, demonstrating an IC50 value of 0.30 μM. It effectively suppresses the production of interleukin-1 beta (IL-1β) while sparing tumor necrosis factor-alpha (TNF-α), making it a valuable tool in the study of inflammation. Notably, YQ128 can penetrate the blood-brain barrier, allowing for potential applications in central nervous system research. Additionally, YQ128 features an alkyne group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc), broadening its utility in click chemistry applications. -
NLRP3 Inhibitor
NP3-562 is a potent, orally active inhibitor of NLRP3, a key component of the inflammasome pathway. It effectively suppresses IL-1β release in Nigericin-stimulated THP-1 cells with an IC50 of 66 nM, and in human whole blood with an IC50 of 214 nM. This compound is valuable for investigating the role of NLRP3 activation in inflammatory conditions, particularly in acute peritonitis models. -
CMV Inhibitor
Soyasaponin II is a saponin known for its antiviral properties, particularly as an inhibitor of cytomegalovirus (CMV) replication. It demonstrates strong efficacy against various viruses, including HSV-1, HCMV, influenza, and HIV-1. Additionally, Soyasaponin II inhibits YB-1 phosphorylation and NLRP3 inflammasome priming, offering potential protective effects in models of acute liver failure induced by LPS/GalN. This compound is valuable for research in virology and inflammation. -
NLRP3 Inhibitor
Usnoflast is a selective, orally active inhibitor of the NLRP3 inflammasome, effectively blocking the release of interleukin-1 beta (IL-1β). Its anti-inflammatory properties make it a valuable tool for research in inflammatory diseases and conditions associated with NLRP3 activation. This compound is instrumental in studying the role of IL-1β in various pathological processes and may aid in the development of novel therapeutic strategies. -
IL-1β Processing Inhibitor
CP-424174 is a reversible inhibitor of IL-1β processing, acting with an IC50 of 210 nM. By indirectly inhibiting the NLRP3 inflammasome, CP-424174 plays a critical role in modulating inflammatory responses. This compound is useful for research applications focused on understanding the mechanisms of inflammation and potential therapeutic interventions in inflammatory diseases. -
BChE Inhibitor
Pteryxin is a potent butyrylcholinesterase (BChE) inhibitor (IC50 = 12.96 μg/mL) with additional multi-target mechanisms including inhibition of NF-κB, MAPK, NLRP3 inflammasome activation, and modulation of the Nrf2/ARE pathways. This compound demonstrates significant anti-inflammatory, antioxidant, and osteoclastogenesis inhibitory activities. Pteryxin is suitable for research applications related to inflammatory diseases, osteoporosis, diabetes, and neurodegenerative disorders such as Alzheimer's disease. -
Proteasome Inhibitor
NIC-0102 is an orally active proteasome inhibitor that specifically targets NLRP3 inflammatory vesicle activation, exhibiting a pIC50 of 7.55. This compound demonstrates significant anti-inflammatory effects in models of dextran sulfate sodium (DSS)-induced ulcerative colitis. Additionally, NIC-0102 is effective in inhibiting the production of pro-IL-1β, making it a valuable tool for research in inflammation and related pathways. -
NLRP3 Inflammasome Inhibitor
NLRP3-IN-17 is a selective and orally bioactive inhibitor of the NLRP3 inflammasome, exhibiting an IC50 value of 7 nM. This compound effectively inhibits NLRP3-dependent secretion of IL-1β in murine models, making it a valuable tool for investigating the mechanisms underlying chronic inflammatory diseases. NLRP3-IN-17 is suited for research applications focused on the modulation of immune responses and the development of therapeutic strategies targeting inflammatory pathways. -
P2Y14R Antagonist
P2Y14R Antagonist 1 is a highly selective antagonist of the P2Y14 receptor, exhibiting an IC50 of 0.6 nM. It demonstrates significant antagonistic activity against P2Y14R, with both in vitro and in vivo efficacy, along with favorable pharmacokinetic properties. This compound effectively reduces the release of inflammatory mediators and mitigates cell pyroptosis through the NLRP3/Gasdermin D signaling pathway. P2Y14R Antagonist 1 is a valuable tool for research investigating acute gouty arthritis and related inflammatory conditions. -
NLRP3 Inhibitor
NLRP3-IN-21 is a selective NLRP3 inflammasome inhibitor that effectively mitigates inflammatory processes. This compound disrupts NLRP3 inflammasome activation and inhibits pyroptosis by preventing gasdermin D cleavage, ASC oligomerization, and the assembly of the inflammasome complex. NLRP3-IN-21 is valuable for research applications focused on understanding inflammatory diseases and developing potential therapeutic strategies targeting the NLRP3 pathway. -
NLRP3 Inhibitor
JT001 sodium is a selective and orally bioavailable inhibitor of the NLRP3 inflammasome. By disrupting NLRP3 assembly, it effectively inhibits the release of pro-inflammatory cytokines and prevents pyroptosis. This compound is valuable for research into nonalcoholic steatohepatitis and liver fibrosis, providing insights into potential therapeutic strategies for these conditions. -
NLRP3 Inhibitor
NLRP3-IN-80 is a selective inhibitor of the NLRP3 inflammasome, a key component in the regulation of inflammatory responses. This compound demonstrates potent inhibitory activity, making it valuable for studying the mechanisms of inflammaging and related inflammatory diseases. NLRP3-IN-80 is suitable for both in vitro and in vivo research applications aimed at understanding chronic inflammation and its implications in various pathologies. -
NLRP3 Inhibitor
NLRP3-IN-2 is a selective inhibitor of the NLRP3 inflammasome, effectively suppressing its formation in cardiomyocytes. This compound demonstrates the ability to reduce infarct size following myocardial ischemia/reperfusion injury in mouse models, while leaving glucose metabolism unaffected. NLRP3-IN-2 is useful in research focused on inflammasome-related pathways and may offer insights into therapeutic strategies for cardiac conditions. -
NLRP3 Inhibitor
AMS-17 is a potent inhibitor of the NLRP3 inflammasome, effectively suppressing microglial activation both in vitro and in vivo. It demonstrates the ability to inhibit the production of key pro-inflammatory cytokines, including caspase-1, TNF-α, IL-1β, and inducible nitric oxide synthase (iNOS) in N9 cells. This compound is valuable for research focused on inflammation-associated neurological disorders, such as vascular dementia (VaD). -
NLRP3 Inhibitor
NLRP3-IN-25 is an orally available NLRP3 inhibitor that exhibits significant anti-inflammatory properties. It effectively reduces renal injury in a doxorubicin-induced glomerulonephritis model in mice. Additionally, NLRP3-IN-25 demonstrates the ability to inhibit IL-1β secretion in THP-1 cells, with an IC50 value of 21 nM, making it a valuable tool for research into NLRP3-related inflammatory conditions. -
Stable Isotope
(±)11(12)-EET-d11 is a deuterium-labeled analog of (±)11(12)-EET, which acts as an inhibitor of the NLRP3 inflammasome. This compound is important for studies investigating anti-inflammatory pathways, angiogenesis, and cardioprotection. The stable isotope labeling allows for enhanced tracking and analysis in various biological assays and helps elucidate the role of (±)11(12)-EET in cellular and molecular processes. -
NLRP3 Inhibitor
Emlenoflast sodium is a potent and selective inhibitor of the NLRP3 inflammasome, exhibiting an IC50 of less than 100 nM. This sulfonylurea compound plays a significant role in studies related to inflammatory diseases, enabling researchers to explore the mechanistic pathways and therapeutic potentials linked to NLRP3 modulation. Its specificity and efficacy make it a valuable tool for investigating the underlying mechanisms of inflammation and related disorders. -
PC Inhibitor
Anemoside A3-methyl 6-aminohexanoate is a potent pyruvate carboxylase (PC) inhibitor, exhibiting a Kd value of 10.1 μM against human PC. This compound influences cellular pathways through the PC/NF-κB/NLRP3 inflammasome axis, demonstrating significant efficacy in alleviating symptoms of DSS-induced colitis in murine models. Anemoside A3-methyl 6-aminohexanoate serves as a useful tool in colitis-related research and studies focusing on the modulation of inflammatory pathways. -
NLRP3 Inhibitor
NLRP3-IN-79 is a potent, orally active inhibitor of the NLRP3 inflammasome, with an IC50 of 10.69 nM. It functions by directly binding to NLRP3, disrupting the NEK7-NLRP3 interaction and preventing inflammasome assembly. This compound is valuable for research into NLRP3-related diseases, such as systemic inflammation, peritonitis, and colitis, facilitating insights into therapeutic strategies targeting inflammasome-mediated pathways. -
NLRP3 Inflammasome Inhibitor
D359-0396 is an orally active inhibitor of the NLRP3 inflammasome. This compound effectively inhibits pyroptosis and the release of IL-1β in macrophages by preventing the oligomerization of NLRP3 and ASC, as well as the cleavage of GSDMD. D359-0396 has demonstrated therapeutic potential in experimental autoimmune encephalomyelitis (EAE) and enhances survival rates in murine models of septic shock. This reagent is suitable for research applications focused on inflammation and immune response modulation. -
NLRP3 Inhibitor
JC-171 is a selective NLRP3 inflammasome inhibitor that demonstrates an IC50 of 8.45 μM in blocking LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages. This compound is valuable for research focused on the roles of NLRP3 in inflammatory diseases, as it allows for the investigation of inflammasome activation and associated cytokine release pathways. Its specificity makes it a useful tool in studying the modulation of innate immune responses in various experimental models. -
NLRP3 Inhibitor
JT001 is a potent and selective orally active inhibitor of NLRP3, targeting the NLRP3 inflammasome. By inhibiting the assembly of the inflammasome, JT001 effectively reduces cytokine release and prevents pyroptosis, allowing for potential therapeutic implications. This compound is valuable for research applications focusing on nonalcoholic steatohepatitis and liver fibrosis. -
NLRP3 Inhibitor
NLRP3-IN-18 is a selective inhibitor of the NLRP3 inflammasome, demonstrating potent activity with an IC50 value of ≤1.0 µM. This compound is instrumental in research focused on inflammation, providing insights into NLRP3-related pathways and their role in various diseases. NLRP3-IN-18 is suitable for studies investigating the modulation of inflammatory responses and the development of therapeutic strategies targeting NLRP3. -
NLRP3 Proteins Inhibitor
NLRP3-IN-11 is a potent inhibitor of NLR family pyrin domain containing 3 (NLRP3) proteins, exhibiting an IC50 value of less than 0.3 μM. It demonstrates significant biological activity in modulating NLRP3 signaling, making it a valuable tool for research into inflammatory and degenerative diseases. Applications include the study of non-alcoholic steatohepatitis (NASH), atherosclerosis, Alzheimer's disease, Parkinson's disease, diabetes, gout, and various autoinflammatory conditions. -
NLRP3 Inhibitor
INF4E is a potent inhibitor of the NLRP3 inflammasome, effectively targeting both caspase-1 and NLRP3 ATPase activities. This compound demonstrates significant protective effects against ischemia-reperfusion-induced myocardial injury and dysfunction. INF4E is valuable for research applications focused on inflammatory diseases and cardioprotection mechanisms.
